Sera Prognostics

The PreTRM test is a single blood draw administered during the 19th or 20th week of pregnancy that measures two protein biomarkers — IBP4 and SHBG — using mass spectrometry. A proprietary algorithm combines the protein ratios with maternal clinical factors to generate a risk score for spontaneous preterm birth before 37 weeks, or more critically before 32 weeks. The test was validated in a multi-center observational study and is processed exclusively at Sera's CLIA-certified laboratory in Salt Lake City.

Zhenya Lindgardt is President and CEO, having taken the reins from co-founder Gregory Critchfield in 2022. Lindgardt previously held senior commercial and corporate development roles at diagnostics firms including Roche Molecular Systems and was a partner at the Boston Consulting Group, focusing on healthcare innovation. The management team also includes a chief medical officer and a chief scientific officer who oversee ongoing clinical trial design and assay development.

Yes. Sera Prognostics completed an initial public offering in July 2021, raising approximately $75 million on the Nasdaq under the ticker SERA. The IPO was complemented by a concurrent private placement of roughly $52 million from a strategic institutional investor. As a public company, Sera files quarterly and annual reports with the SEC that detail cash position, revenue, and test-volume metrics.

The pivotal clinical study was the PREVENT-PTB trial, a prospective observational study that enrolled over 5,500 women across more than a dozen US sites. Published results showed that women flagged as high-risk by the PreTRM test delivered preterm at a significantly elevated rate compared to low-risk women, with the strongest predictive performance for deliveries before 32 weeks. The company has also published economic analyses suggesting that targeted intervention following a high-risk result can reduce neonatal ICU days by several hundred dollars per screened pregnancy (per peer-reviewed publications, 2020–2022).

Revenue comes primarily from per-test reimbursement for the PreTRM test. Sera bills commercial insurers, state Medicaid programs, and occasionally self-pay patients. The reimbursement pathway depends on securing in-network contracts or favorable medical-policy coverage decisions, one regional payor at a time. At present, the company remains pre-revenue-at-scale, reporting modest test volumes and investing heavily in salesforce expansion to build top-line growth.

Sera Prognostics was co-founded by Gregory Critchfield, a former senior executive at Myriad Genetics and a clinical pathologist, with early scientific collaborations drawing on the maternal-fetal medicine research community around Salt Lake City-based Intermountain Healthcare and the University of Utah. The company has conducted multiple clinical studies at Intermountain sites and maintains independent laboratory operations, not structured as a university spinout but rather as an independent corporation with local research ties.

The immediate competitive landscape has been thin; no other CLIA-certified proteomic blood test for preterm birth risk prediction has gained equivalent commercial traction or guideline inclusion as of early 2025. Historical attempts to predict preterm birth using fetal fibronectin swabs or cervical-length ultrasound provide complementary rather than substitutive information. Sera's primary competitive moat is the multi-year lead in building a clinical-utility evidence package that protocol-driven payors demand.